44,100 Shares in Ionis Pharmaceuticals Inc (IONS) Acquired by Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 44,100 shares of the company’s stock, valued at approximately $2,384,000.

Several other hedge funds also recently made changes to their positions in the business. Huntington National Bank boosted its stake in shares of Ionis Pharmaceuticals by 159.3% in the fourth quarter. Huntington National Bank now owns 638 shares of the company’s stock valued at $34,000 after buying an additional 392 shares in the last quarter. Essex Savings Bank purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $43,000. Daiwa Securities Group Inc. boosted its stake in shares of Ionis Pharmaceuticals by 29.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after buying an additional 200 shares in the last quarter. Finally, Portfolio Solutions LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $54,000. Institutional investors own 85.05% of the company’s stock.

A number of analysts recently weighed in on the company. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald assumed coverage on Ionis Pharmaceuticals in a research note on Tuesday, April 9th. They issued a “neutral” rating and a $68.00 price target on the stock. Piper Jaffray Companies set a $75.00 price target on Ionis Pharmaceuticals and gave the company a “neutral” rating in a research note on Friday, March 22nd. JPMorgan Chase & Co. lifted their price objective on Ionis Pharmaceuticals from $47.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, March 18th. Finally, ValuEngine raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $66.33.

In other news, Chairman Stanley T. Crooke sold 77,000 shares of the business’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $60.77, for a total value of $4,679,290.00. Following the completion of the transaction, the chairman now directly owns 109,634 shares of the company’s stock, valued at $6,662,458.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Richard S. Geary sold 46,240 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $84.01, for a total value of $3,884,622.40. Following the completion of the transaction, the senior vice president now directly owns 45,442 shares of the company’s stock, valued at $3,817,582.42. The disclosure for this sale can be found here. Over the last three months, insiders sold 339,205 shares of company stock valued at $24,034,607. Insiders own 2.44% of the company’s stock.

IONS stock traded down $0.73 during midday trading on Monday, hitting $83.88. 922,720 shares of the stock were exchanged, compared to its average volume of 1,027,495. The stock has a market cap of $11.70 billion, a PE ratio of 28.34, a P/E/G ratio of 256.41 and a beta of 2.42. Ionis Pharmaceuticals Inc has a fifty-two week low of $39.07 and a fifty-two week high of $86.58. The company has a debt-to-equity ratio of 0.53, a quick ratio of 7.85 and a current ratio of 7.88.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 27th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $2.46. The firm had revenue of $192.00 million during the quarter, compared to analysts’ expectations of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. Ionis Pharmaceuticals’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share. As a group, equities research analysts predict that Ionis Pharmaceuticals Inc will post 0.02 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-acquires-new-stake-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: What is a Stop Order?

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.